Vivos Therapeutics (VVOS) Director Gregg C. Johnson Receives Option Grant

What Happened

• Gregg C. Johnson, a director of Vivos Therapeutics (VVOS), was granted 12,000 stock options on September 14, 2026 (reported as an acquisition/award). The filing lists the transaction price as $0.00 for reporting purposes; this reflects a grant of options rather than an open‑market purchase. The options are exercisable for 10 years from the grant date.

Key Details

• Transaction date: September 14, 2026; Form 4 filed September 18, 2026 (filed 4 days after the grant).
• Grant size: 12,000 stock options (reported at $0.00 in the Form 4).
• Vesting: 6,000 options (1/2) vested immediately; 3,000 (1/4) vest on September 30, 2026; 3,000 (1/4) vest on December 31, 2026.
• Exercise term: Options exercisable for 10 years from the grant date.
• Shares owned after transaction: Not specified in the filing; footnote indicates holdings are held by Spite Family Holdings LP, an affiliate of the reporting person.
• Filing timeliness: Form 4 was filed four days after the grant (Form 4s are generally due within two business days), so this filing appears later than the typical reporting window.

Context

• This was an option grant (award), not a cash purchase or sale. One-half of the award vested immediately, which enables immediate exercise for that tranche if the holder chooses; the filing does not indicate any exercise or sale occurred. Option grants inform investors about company compensation and possible future insider purchases but do not by themselves indicate buying or selling of shares.